Rectal Ozone as Neuroprotector Post CNS Insult in Children
NCT ID: NCT07153627
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2025-05-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Different Reversal Agents in Pediatric Day-case Cancer Surgery
NCT03996655
Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants
NCT02708056
The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
NCT06035757
Assessment of Therapeutic Effect of Rectal Vs. Intravenous Paracetamol in The Treatment of Patent Ductus Arteriosus (PDA) in Neonates
NCT06256211
Sugammadex Versus Neostigmine in Pediatric Less Than Two Years Undergoing Cardiac Catheterization
NCT04258007
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ozone (O3) gas was discovered in the 1840s, and soon after that, the scientific community began to expand past the notion that it was just another gas of the Earth's atmosphere.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
Patients will receive 40 Rectal ozone sessions or until improvement (maximum 80 sessions), in addition to their conventional rehabilitation program.
Rectal ozone sessions
Patients will receive 40 Rectal ozone sessions or until improvement (maximum 80 sessions), in addition to their conventional rehabilitation program.
Group 2
Patients will receive their conventional rehabilitation program only (physiotherapy sessions three times per week for the treatment period (six months).
Conventional rehabilitation program
Patients will receive their conventional rehabilitation program only (physiotherapy sessions three times per week for the treatment period (six months).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rectal ozone sessions
Patients will receive 40 Rectal ozone sessions or until improvement (maximum 80 sessions), in addition to their conventional rehabilitation program.
Conventional rehabilitation program
Patients will receive their conventional rehabilitation program only (physiotherapy sessions three times per week for the treatment period (six months).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Children admitted to the pediatric intensive care unit (PICU) with acquired neurological insult.
* Children with neurological sequelae
* Children who are exposed to acquired brain injury, e.g., traumatic brain injury, cardiac arrest, intracranial hemorrhage, central nervous system infections, stroke, tumor, or hypoxia, with neurological sequelae diagnosed by neurological examination and magnetic resonance imaging (MRI), to detect that disorder early.
Exclusion Criteria
* Patients not fit for Rectal ozone therapy.
* Patients with active epilepsy and recurrent seizures.
* Children with a positive family history of degenerative brain insults.
* Children with behavioral problems.
1 Month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Al-Azhar University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mohamed Abd ELgawad Mohamed Asfour
Assistant Lecturer of Pediatrics, Faculty of Medicine, Al-Azhar University, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al-Azhar University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KFSIRB200-623
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.